Table 1.
Results of principal anti-vascular endothelial growth factor studies in age-related macular degeneration.
| Name of study | Type of study | Patients (n) | Treatment modality | Choroidal neovascularization type | Losing fewer than 15 letters at year 11 | Losing fewer than 15 letters at 2 years1 | Improvements of 1 or more lines in vision at year 11 | Improvements of 1 or more lines in vision at year 21 | Duration |
|---|---|---|---|---|---|---|---|---|---|
| VISION | RCT | 1186 | Monthly intravitreal injections of pegaptanib or sham treatment | All subfoveal angiographic lesion types | yes | 2 years | |||
| MARINA | RCT | 716 | Monthly intravitreal injections of 0.3 or 0.5 mg of Ranibizumab or sham treatment | Minimally classic or purely occult choroidal neovascularization | yes | yes | yes | yes | 2 years |
| ANCHOR | RCT | 423 | Monthly intravitreal injections of 0.3 or 0.5 mg of Ranibizumab or standard PDT indicated at 3 month intervals | Predominantly classic subfoveal choroidal neovascularization because of AMD | yes | yes | 2 years | ||
| PIER | RCT | 182 | Ranibizumab intravitreal administrations monthly for three doses followed by dosing 0.3 or 0.5 mg every 3 months or sham treatment | All types of choroidal neovascularization | yes | yes | yes | 2 years | |
| SUSTAIN | RCT | 531 | Whether treatment naïve or completed treatment with ranibizumab or verteporfin photodynamic therapy | All subfoveal angiographic lesion types | yes | 1 year | |||
| EXCITE | RCT | 353 | 0.3 mg quarterly, 0.5 mg quarterly or 0.3 mg monthly doses of ranibizumab. After a loading phase of 3 consecutive monthly injections | All subfoveal angiographic lesion types | yes | 1 year | |||
| PRONTO | Prospective, uncontrolled | 40 | Loading phase of 3 consecutive monthly intravitreal injections of ranibizumab 0.5 mg followed by retreatment in case of OCT evidence | All subfoveal angiographic lesion types | yes | yes | 2 years |
Statistically significant difference between the sham/no ranibizumab treatment and doses of ranibizumab administered.
Abbreviations: RCT, randomized controlled trial; VISION, VEGF inhibition study in ocular neovascularization; MARINA, Minimally classic/occult trial of the Anti-VEGF antibody ranibizumab in the treatment of neovascular AMD; ANCHOR, Antivascular endothelial growth factor (VEGF) antibody for the treatment of predominantly classic choroidal neovascularization (CNV) in age-related macular degeneration; PIER, Phase IIIb, multicenter, randomized, double-masked, sham injection-controlled study of efficacy and safety of ranibizumab in subjects with subfoveal choroidal neovascularization with or without classic CNV secondary to age-related macular degeneration; SUSTAIN, Study of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration; EXCITE, Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration; PRONTO, Prospective optical coherence tomography (OCT) imaging of patients with neovascular age-related macular degeneration (AMD) treated with intra-ocular Lucentis™ (ranibizumab)